MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Mesothelioma Drug In Progress

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Mesothelioma Drug In Progress

Mesothelioma Drug In Progress
CuraGen Corporation and TopoTarget have initiated patient dosing in a phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase inhibitor, for the treatment of a type of cancer called mesothelioma.

Mesothelioma is a type of cancer arising from the cells, known as mesothelium, with the majority of cancers beginning in the chest cavity. The incidence of mesothelioma increases with age and is rarely diagnosed in patients under 55 years old. Exposure to asbestos is believed to be the main cause of the disease.

National Cancer Institute is sponsoring the current clinical trial with CuraGen. Those who are having a diagnosis of mesothelioma, which is not removable by surgery and who have failed at least one line of chemotherapy are eligible for the clinical trial. The drug PXD101 is given by intravenous infusion once every three weeks.

The scientists are trying to determine if the drug PXD101 has any significant activity on mesothelioma in terms of clinical response. The study is also aimed at determining the safety of the drug and time to therapy failure. The study would also look for any survival advantage resulting from the use of the drug.

Scientists are planning to enroll a total of 37 patients at different sites across the United States.

Histone deacetylase inhibitors have the ability to down-regulate genes such as BCL-XL and VEGF and up-regulate cell-cycle regulating genes, including p21. Scientists say that they are excited to begin the trial and would evaluate PXD101 as a potential therapy for mesothelioma.

Sadly, there are no proven therapies available for patients who have progressed on the first line chemotherapy. PXD101 is expected to take this vacant position in the therapy algorithm.




Did you know?
CuraGen Corporation and TopoTarget have initiated patient dosing in a phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase inhibitor, for the treatment of a type of cancer called mesothelioma. Mesothelioma is a type of cancer arising from the cells, known as mesothelium, with the majority of cancers beginning in the chest cavity. The incidence of mesothelioma increases with age and is rarely diagnosed in patients under 55 years old. Exposure to asbestos is believed to be the main cause of the disease.

Medicineworld.org: Mesothelioma Drug In Progress

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.